FDA Refreshes Drug Approvals and Databases Portal Across 20 Regulatory Tools

Regulatory affairs leads and QA directors working across NDA submissions, REMS compliance, and postmarketing commitments now have a consolidated reference point: FDA's Drug Approvals and Databases page has been updated to surface more than 20 searchable tools and downloadable resources under a single URL. The update, published via CDER's What's New feed, reflects the agency's ongoing effort to centralise access to compliance-critical data.

For manufacturing and quality teams, the most operationally relevant tools include the Drug Establishments Current Registration Site, which supports verification of outsourcing facility registration status, and the Outsourcing Facility Product Report, relevant to any site operating under 21 CFR Part 503B. The Dissolution Methods Database and Inactive Ingredient Search remain standard reference points during formulation development and process validation activities.

Postmarketing obligations carry their own compliance weight. The Postmarketing Requirements and Commitments Searchable Database allows regulatory teams to track open commitments against approval conditions, while the Drug Safety-related Labeling Changes (SrLC) resource provides a running record of label updates that may trigger downstream CAPA or change-control activity. Both tools are directly relevant to ICH Q10-aligned pharmaceutical quality systems.

Supply-chain and shortage monitoring functions are also consolidated here. The Drug Shortages database and the FDA Adverse Event Monitoring System (AEMS) Public Dashboard, alongside its quarterly downloadable data files, give pharmacovigilance and supply teams structured access to signal data without requiring a formal data request. The National Drug Code Directory and Wholesale Distributor and Third-Party Logistics Providers Reporting tool round out the distribution-side compliance resources.

For generic development programmes, the Product-Specific Guidances for Generic Drug Development Database and the Orange Book remain the primary references for therapeutic equivalence evaluations, while the Purple Book covers FDA-licensed biological products, biosimilars, and interchangeable designations. OTC Monographs@FDA and the PEPFAR Database address more specialised submission contexts.

Labelling resources, including FDALabel, the FDA Online Label Repository, and FDA's Labeling Resources for Human Prescription Drugs, are grouped alongside approval activity reports: the Compilation of CDER NME Drug and New Biologic Approvals, Drug and Biologic Approval and IND Activity Reports, and This Week's Drug Approvals. Oncology and haematologic malignancy approval notifications are listed separately, reflecting CDER's therapeutic area prioritisation.

Teams conducting periodic reviews of their postmarketing commitments or preparing for pre-approval inspections should confirm that their internal tracking aligns with the current state of each relevant database before the next scheduled agency interaction.

Source: FDA CDER via What's New: Drugs RSS Feed, 28 October 2026.